News

Sana Announces Closing of Initial Public Offering

Sana Biotechnology, a UCSF startup company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $675.6 million. All of the shares of common stock were...

Weill Neurohub Joins Forces with Genentech and Roche to Advance Neuroscience Research

UC San Francisco and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS),...

‘AutoImmunoprofiler’ Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases

UCSF Partners With Eli Lilly to Better Understand Underlying Drivers of Autoimmunity and Accelerate the Development of Better Therapies.  MORE

Calico and AbbVie Take UCSF Technology Into Clinical Trials

Calico Life Sciences and AbbVie announced clinical-stage programs in two areas – immuno-oncology and neurodegeneration, currently in Phase I studies. The lead Calico neurodegeneration molecule is based on novel technology licensed from the lab of Peter Walter, Professor of Biochemistry and...

Sana Biotechnology Files for IPO

UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. MORE

'Invisible' stem cells evade natural killer cells using immune 'off-switch'

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer...

Alliance Management an Integral Part of Successful Industry Engagement

Convincing a potential industry partner that an initial collaboration is attractive is one thing; keeping that partner on board and strengthening that relationship as the years go on is quite another, and that’s where alliance management comes in. Peter Kotsonis, UCSF's Strategic Alliances...

UCSF and BridgeBio Pharma to Accelerate Therapies for Genetic Diseases

SAN FRANCISCO – December 23, 2020 - UC San Francisco and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

Autobahn Collaboration to Accelerate UCSF Innovation from Bench to Bedside

Partnership with Autobahn Labs Aims to Pave Road Through ‘Valley of Death’ Faced by Novel Therapies

UCSF Startup Siolta and Bio-Me to Collaborate

Bio-Me and UCSF startup Siolta Therapeutics, founded by Professor Susan Lynch, aim to develop and market predictive test for infants to determine microbiome-based pediatric allergies and asthma. More